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Abstract
We present a case of an individual with cirrhosis and renal failure. This case is notable because the patient was found to have
hepatorenal syndrome (HRS) superimposed on Immunoglobulin A (IgA) nephropathy. After 8 months of dialysis, the patient
had signiﬁcant renal recovery following orthotopic liver transplant (OLT). Cases such as this are not likely to be rare, as case
series have shown that IgA deposits are a common occurrence in patients with cirrhosis, including those who have HRS.
While current diagnostic criteria for HRS emphasize the importance of excluding glomerular lesions, we argue that this approach
should be reconsidered. More speciﬁcally, we feel that the diagnostic approach to HRS should be more inclusive of cases in which
patients have simultaneous HRS and glomerular injury. In addition, our case highlights the challenges in determining which
patients will beneﬁt most from simultaneous liver–kidney transplants over OLTs alone.
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Introduction
Kidney injury in the setting of cirrhosis is a common phenom-
enon. A number of different renal pathologies are commonly
associated with liver disease, including Immunoglobulin A
(IgA) nephropathy, cryoglobulinemia, membranous nephropa-
thy, membranoproliferative glomerulonephritis, and hepatore-
nal syndrome (HRS) (1–3). For treating kidney disease, a
number of treatment options exist, which vary based on the
cause of the kidney injury. Orthotopic liver transplant (OLT)
has been well described as a deﬁnitive treatment in some
cases of HRS (4). Our understanding of why some patients
with HRS recover renal function after OLT and why others
do not is limited; however, some data suggest that duration of
kidney injury prior to transplant is an important factor (5).
Duration of injury is a plausible factor, as it is well appreciated
that the common ﬁnal pathway for all kidney injury, irrespec-
tive of initial etiology, is diffuse, irreversible ﬁbrosis (6).
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Therefore, it is reasonable to speculate that during prolonged
courses of HRS, the injury transforms from a functional change
in renal function to an irreversible injury on the pathway to
ﬁbrosis. However, it is unclear what speciﬁc factors dictate
the timing of this transformation in HRS. Therefore, signiﬁcant
challenges exist regarding the prediction of whether a given
individual will actually recover renal function after OLT or
not, as there is likely to be signiﬁcant heterogeneity with respect
to the time it takes to develop irreversible kidney injury among
subjects with HRS. Under the current Organ Procurement
and Transplantation Network (OPTN) policy, adult candidates
seeking simultaneous liver–kidney transplantation (SLK) must
meet one of the following medical eligibility criteria: (i) presence
of chronic kidney disease (CKD) deﬁned as a glomerular
ﬁltration rate (GFR) <60 mL/min for ≥90 days and either on
dialysis as an end-stage renal disease (ESRD) patient or a
creatinine clearance (CrCl) or estimated glomerular ﬁltration
rate (eGFR) of ≤30 mL/min at the time of kidney transplant
listing, (ii) sustained acute kidney injury (AKI) deﬁned as a
CrCl or eGFR ≤25 mL/min or dialysis dependence lasting for
at least 6 weeks, or (iii) one of several metabolic diseases (7).
The appropriateness of these criteria has been under debate
since it was adopted in 2016 (8, 9). In this article, we report a
case of a patient with ESRD in the setting of liver cirrhosis
from alpha-1 antitrypsin deﬁciency (A1ATD) who recovered
renal function following OLT. Our case is notable as the subject
had prolonged kidney injury, requiring hemodialysis (HD) for
8 months, but still regained signiﬁcant renal function. Our
case is important to report in the literature because it adds per-
spective to the challenges of diagnosing HRS as well as deter-
mining eligibility for SLK in patients with cirrhosis and CKD.
Case report
A 56-year-old male with decompensated cirrhosis secondary to
A1ATD type ZZ/30 presented with AKI. The patient’s renal
dysfunction was ﬁrst noted on surveillance lab work, which
revealed an elevated serum creatinine of 1.9mg/dL (from a base-
line of 1.0 mg/dL). His creatinine initially improved after discon-
tinuation of diuretics and transition to large volume
paracenteses (LVPs) for volume control. However, about 1
month later his serum creatinine rose to 3.4 mg/dL, prompting
a hospital admission for expedited evaluation of his subacute
kidney injury.
Despite having developed AKI in the setting of decompen-
sated cirrhosis, the diagnosis of HRS as the etiology of his
AKI was only transiently entertained. On admission, his
urine electrolytes were consistent with pre-renal AKI and the
renal function failed to improve after a trial of intravascular
volume expansion challenge, both of which can be suggestive
of HRS. Furthermore, he had no known recent exposure to
nephrotoxins and no evidence of shock or hemodynamic com-
promise; renal ultrasound was unremarkable. However, his
urinalysis was signiﬁcant for 3+ proteinuria (spot urine pro-
tein:creatinine = 1400mg/gCr), and urinemicroscopy revealed
an active urine sediment, including dysmorphic red blood cells
with both granular and red blood cells casts. This suggestion of
intrinsic renal disease challenged the diagnosis of HRS, which
is currently a diagnosis of exclusion.
A renal biopsy was performed, and the light microscopy
slides showed diffuse acute tubular injury, mesangial prolifera-
tion, and focal interstitial inﬁltrate with lymphocytes. Immuno-
ﬂuorescence studies revealed 3+ IgA and C3 deposition in the
mesangium and 1+ positivity for IgM in capillary loops. IgG
was negative. Electron microscopy showed increased mesangial
matrix deposits. Based on these biopsy ﬁndings, the patient was
diagnosed with IgA nephropathy, for which he was treated with
lisinopril, ﬁsh oil, and prednisone.
The patient’s renal dysfunction progressed to end-stage renal
failure in coming weeks and hemodialysis was initiated. He
was subsequently listed for SLK on the advice of his clinicians.
His model for end-stage liver disease (MELD) score was 34.
After awaiting dual organ offers for several months, the patient
decided to change his listing status toOLTalone.Themotivation
behind this was that his anticipated waiting time for an OLT
alone would be much shorter than an SLK. Three days after
unlistinghimself for dual organ transplant, thepatient underwent
OLT.
FollowingOLT, the patient’s average pre-hemodialysis serum
creatinine improved from 7.1 mg/dL to 1.5 mg/dL. A measured
CrCl was found to be 39 mL/min. Hemodialysis was subse-
quently discontinued. Two years post-OLT, his renal recovery
has persisted. He has remained off of HD, and his creatinine
has stabilized at 1.4–1.7 mg/dL (eGFR 40–50 mL/min). Given
his degree of renal recovery following OLT, the patient was
retrospectively diagnosedwithHRSdespite the presence of struc-
tural renal injury.
Discussion
Our case is noteworthy for a few reasons. First, it highlights the
challenge of diagnosing HRS despite the existence of estab-
lished diagnostic criteria, and it serves as a reminder to clini-
cians to consider this diagnosis in cirrhotic patients with
renal dysfunction despite evidence of glomerular disease in
the urine or on kidney biopsy. Second, it demonstrates the
difﬁculty of deciding whether a cirrhotic patient with CKD
should be eligible for an SLK, even in those with prolonged
ESRD. Furthermore, it suggests that under the current
OPTN/United Network for Organ Sharing (UNOS) medical
eligibility criteria established for kidney allocation to SLK
candidates, a signiﬁcant proportion of patients are likely to
receive a kidney graft that they do not need.
HRS is understood to be a functional injury to the kidneys
involving maladaptive hemodynamic changes that include
increases in nitric oxide-mediated splanchnic arterial dilatation
and the compensatory upregulation of the renin–angiotensin–
aldosterone system and sympathetic nervous system leading
to renal vasoconstriction (10, 11). The current paradigm by
which we diagnose HRS emphasizes it as a diagnosis of
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exclusion. The International Ascites Club (IAC) HRS diagnos-
tic criteria infer that the probability of a patient having HRS
increases with the exclusion of shock, nephrotoxin exposure,
and glomerular injury (based on the presence of signiﬁcant pro-
teinuria [>500 mg/24 hours] or hematuria [>50 RBC/hpf]). This
is a challenging proposition because there is no pathophysiolo-
gic reason that HRS could not be present concurrently with
ischemic/nephrotoxic acute tubular injury or glomerular injury.
A more appropriate approach to emphasize may be to ponder
whether HRS is the sole cause of kidney injury or whether it is
superimposed on another etiology. Given that patients with
cirrhosis are severely ill, they are undoubtedly at high risk of
many types of renal insults. Lowmean arterial pressures, gastric
varices, and impaired coagulation function make ischemic
injury common. Frequent exposure to infections, antibiotics,
contrast dye, and proton pump inhibitors makes nephrotoxic
injury common. In addition, it has been well documented
since the 1940s that the majority of cirrhotic patients have
biopsy-proven glomerular abnormalities, many of which con-
tain IgA deposits, as was the case with our patient (12–23).
Thus, the likelihood of having IgA deposits in a patient with
cirrhosis and simultaneous HRS is not likely to be rare. The
subject we report on had AKI andmet ﬁve out of the six criteria
for the diagnosis of HRS based on the 2015 ICA diagnostic
guidelines. However, HRS was excluded as a diagnosis because
his AKIwas associated with the presence of an active urine sedi-
ment and a biopsy that conﬁrmed IgA mesangial deposits. It
was not until our patient had been on HD for 8 months and
then had dramatic renal recovery immediately following OLT
that the diagnosis of superimposed HRS was conﬁrmed. This
case therefore highlights the challenges associated with diagnos-
ing HRS in patients with simultaneous glomerular disease.
Given the relative scarcity of organs available for trans-
plant, it is imperative that cirrhotic patients with reversible
kidney injury are accurately distinguished from those who
have irreversible kidney injury in order to ensure just alloca-
tion of resources. Incorrectly diagnosing cirrhotic patients
with irreversible renal failure leads to needlessly listing these
patients for SLK. On an individual level, this translates to
increased time on the transplant waitlist and its associated
stress, anxiety, and relative negative quality of life (24–26).
On a societal level, this means that fewer kidneys are available
to ESRD patients, who face a 6% annual mortality on the
kidney transplant waitlist (27).
Although our patient met eligibility for SLK based on
the current criteria, his renal outcome was excellent after
OLT alone. Therefore, this case underscores the challenges
in rightly allocating kidneys for transplantation in patients
with cirrhosis and kidney disease. Data show that those
with mild CKD are not likely to beneﬁt from SLK (7, 28).
In terms of those with severe kidney disease or those requiring
dialysis prior to transplant, data show a small survival beneﬁt
of about 5% at 1 year in those undergoing SLK versus OLT
alone (29). However, the beneﬁt of SLKmay be especially dif-
ﬁcult to determine in patients with HRS. Data from a single
center showed that 33% of patients with HRS undergoing
SLK had signiﬁcant recovery of their native renal function
post-transplant (30). Many of the kidneys being used for
SLK have a low Kidney Donor Proﬁle Index (KDPI) score
(<35%). This has raised concerns among somemembers of the
transplant community that organs with an expected long-term
survival are preferentially being given to older recipients
awaiting SLK over younger recipients awaiting an OLT
alone (8, 9).
Conclusion
This case highlights the challenges associated with diagnosing
HRS in patientswith simultaneous glomerular disease.We feel
it warrants a change in how we think about and discuss HRS.
Clinical reasoning surrounding the diagnostic approach to
HRS should be more inclusive of cases in which patients
have HRS simultaneous to glomerular injury. Clinicians
should be wary of excluding the diagnosis solely based on
the presence of an active urine sediment. In addition, it should
cause us to rethink if there is any role for performing a kidney
biopsy in these patients. It is well appreciated that the bleeding
and infection risk of performing a kidney biopsy is high in this
population, but it should also be well appreciated that ﬁnding
glomerular injury or other structural changes on biopsy will
not by itself exclude HRS. This further re-enforces the fact
that the risks associatedwith kidney biopsy in patients with cir-
rhosis far outweigh any potential beneﬁts.
Furthermore, we hope that being familiar with cases such as
ours, and similar ones reported in the literature (31), clinicians
will more carefully consider for whom SLK is truly appropri-
ate. The current medical eligibility criteria set the minimum
duration during which kidney disease must be met for patients
to be considered for SLK. It is critical that this should not be
interpreted as a mandate that all patients who meet criteria
undergo SLKas opposed toOLTalone.Our patient had excel-
lent renal outcomes with OLT alone, despite meeting the cri-
teria for SLT. We therefore argue that each case must be
individually evaluated.
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